Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

Leukemia. 2018 Jan;32(1):241-244. doi: 10.1038/leu.2017.285. Epub 2017 Sep 18.

Authors

P Boddu¹, J Jorgensen², H Kantarjian¹, G Borthakur¹, T Kadia¹, N Daver¹, Y Alvarado¹, N Pemmaraju¹, P Bose¹, K Naqvi¹, M Yilmaz¹, S Pierce¹, M Brandt¹, C D DiNardo¹, E J Jabbour¹, M Konopleva¹, G Garcia-Manero¹, J Cortes¹, F Ravandi¹

Affiliations

¹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 28919634
DOI: 10.1038/leu.2017.285

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Methylation / drug effects*
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Neoplasm, Residual / drug therapy*
Prognosis
Recurrence
Risk

Substances

Antineoplastic Agents

Grants and funding